In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.
Magazine
Adiarin® is recommended for the protection of gut lining in diarrhea in children and adults. It is the first Noventure product in Russia.
Tasectan® in Europe is a class III medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE 0373, Novinthetical Pharma SA). In Russia, Adiarin® has been granted local marketing authorization as class II medical device.
Clarifying the role of intestinal mucus in reducing inflammation and infection has led to the development of ‘mucosal protectors’. These agents form a bioprotective film in the gastrointestinal tract and potentially may prevent microorganisms from crossing the mucus barrier. To date, the most widely studied substances include xyloglucan (Xilaplus®) and gelatin tannate (Tasectan®, Gelenterum®). 2 new clinical studies are about to start to increase the body of evidence of those substances.
Szajewska H, Kołodziej M, Łukasik J. Drug development and acute gastrointestinal infections. Expert Opin Investig Drugs. 2017 Dec 26:1-6
We are pleased to announce the launch of Tasectan® Duo in Austria by our partner company Montavit. This will be Tasectan® Duo´s second market, after the successful introduction in Italy by Angelini.
Tasectan Duo ® is the first combination of gelatin tannate and inactivated bacteria, and can be used to re-establish the physiological functions of the gut barrier, as well as to prevent dysbiosis.
It is intended for prolonged diarrhea (lasting between 1 - 2 weeks) or for the prevention and management of diarrhea associated with antibiotic treatment, and is expected to capture part of the market space of probiotics used for diarrhea.
